99 related articles for article (PubMed ID: 8729161)
1. Serum lipid and lipoprotein metabolism after glucose ingestion in NIDDM and IGT patients. Apolipoprotein-containing particles.
Nagai T; Tomizawa T; Minamide S; Nakajima K; Mori M
Diabetes Care; 1996 Apr; 19(4):365-8. PubMed ID: 8729161
[TBL] [Abstract][Full Text] [Related]
2. Effect of nephropathy on the composition of apolipoprotein-containing particles in NIDDM.
Nagai T; Tomizawa T; Nakajima K; Uehara Y; Mori M
J Atheroscler Thromb; 1998; 5(2):54-9. PubMed ID: 10855558
[TBL] [Abstract][Full Text] [Related]
3. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance.
Fujiwara R; Kutsumi Y; Hayashi T; Nishio H; Koshino Y; Shimada Y; Nakai T; Miyabo S
Am J Cardiol; 1995 Jan; 75(2):122-6. PubMed ID: 7810485
[TBL] [Abstract][Full Text] [Related]
4. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients.
Watanabe N; Taniguchi T; Taketoh H; Kitagawa Y; Namura H; Yoneda N; Kurimoto Y; Yamada S; Ishikawa Y
Diabetes Care; 1999 Jan; 22(1):152-6. PubMed ID: 10333918
[TBL] [Abstract][Full Text] [Related]
5. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
Nagai T; Tomizawa T; Nakajima K; Mori M
J Atheroscler Thromb; 2000; 7(2):91-6. PubMed ID: 11426588
[TBL] [Abstract][Full Text] [Related]
6. Impaired glucose tolerance without hypertriglyceridemia does not enhance postprandial lipemia.
Higashi K; Shige H; Ito T; Nakajima K; Ishikawa T; Nakamura H; Ohsuzu F
Horm Metab Res; 2001 Feb; 33(2):101-5. PubMed ID: 11294490
[TBL] [Abstract][Full Text] [Related]
7. Remnant-like particles (RLP) from NIDDM patients with apolipoprotein E3/3 phenotype stimulate cholesteryl ester synthesis in human monocyte-derived macrophages.
Saito M; Eto M; Okada M; Iwashima Y; Makino I
Artery; 1996; 22(3):155-63. PubMed ID: 8893973
[TBL] [Abstract][Full Text] [Related]
8. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study.
Frénais R; Ouguerram K; Maugeais C; Mahot P; Maugère P; Krempf M; Magot T
Diabetologia; 1997 May; 40(5):578-83. PubMed ID: 9165227
[TBL] [Abstract][Full Text] [Related]
9. Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans.
Park JS; Cho MH; Nam JS; Yoo JS; Lee YB; Roh JM; Ahn CW; Jee SH; Cha BS; Lee EJ; Lim SK; Kim KR; Lee HC
Metabolism; 2010 May; 59(5):677-82. PubMed ID: 19914667
[TBL] [Abstract][Full Text] [Related]
10. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM.
Motala AA; Omar MA; Gouws E
Diabetes Care; 1997 Jul; 20(7):1101-7. PubMed ID: 9203444
[TBL] [Abstract][Full Text] [Related]
11. The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes.
Taggart C; Gibney J; Owens D; Collins P; Johnson A; Tomkin GH
Diabet Med; 1997 Dec; 14(12):1051-8. PubMed ID: 9455933
[TBL] [Abstract][Full Text] [Related]
12. [Serum lipids and apolipoproteins AI, B100, CI and CII in patients with apoplexy].
Liu BW; Zhang ZH; Wu ZF; Fu MD; Zhang RJ; Fan P; Zhang P; Hu CH; Luo ZM; She LM
Hua Xi Yi Ke Da Xue Xue Bao; 1989 Mar; 20(1):9-12. PubMed ID: 2507441
[TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemia in different degrees of glucose intolerance in a Finnish population-based study.
Salomaa VV; Tuomilehto J; Jauhiainen M; Korhonen HJ; Stengård J; Uusitupa M; Pitkanen M; Penttila I
Diabetes Care; 1992 May; 15(5):657-65. PubMed ID: 1516486
[TBL] [Abstract][Full Text] [Related]
14. Apolipoproteins AI and B and plasma lipid values in well-treated diabetic patients from Romania.
Dabelea D; Serban V; Băcanu G; Deutsch G; Pataki C; Dan I
Rom J Intern Med; 1995; 33(3-4):249-56. PubMed ID: 8646198
[TBL] [Abstract][Full Text] [Related]
15. Impaired glucose tolerance and NIDDM: does a lifestyle intervention program have an effect?
Bourn DM; Mann JI; McSkimming BJ; Waldron MA; Wishart JD
Diabetes Care; 1994 Nov; 17(11):1311-9. PubMed ID: 7821173
[TBL] [Abstract][Full Text] [Related]
16. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM.
Haffner SM; Agil A; Mykkanen L; Stern MP; Jialal I
Diabetes Care; 1995 May; 18(5):646-53. PubMed ID: 8586002
[TBL] [Abstract][Full Text] [Related]
17. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
Battula SB; Fitzsimons O; Moreno S; Owens D; Collins P; Johnson A; Tomkin GH
Metabolism; 2000 Aug; 49(8):1049-54. PubMed ID: 10954025
[TBL] [Abstract][Full Text] [Related]
18. Relationship of low-density lipoprotein particle size to plasma lipoproteins, obesity, and insulin resistance in Japanese men.
Suehiro T; Ohguro T; Sumiyoshi R; Yasuoka N; Nakauchi Y; Kumon Y; Hashimoto K
Diabetes Care; 1995 Mar; 18(3):333-8. PubMed ID: 7555476
[TBL] [Abstract][Full Text] [Related]
19. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Pietzsch J; Julius U; Nitzsche S; Hanefeld M
Diabetes; 1998 Dec; 47(12):1928-34. PubMed ID: 9836526
[TBL] [Abstract][Full Text] [Related]
20. [Strategies for early detection of the risk of type II (non-insulin-dependent) diabetes in 1st degree relatives of patients with this disease].
Kasperska-Czyzykowa T; Jedynasty K; Jaskólska-Ładosz K; Stefański P; Milczarczyk A
Pol Arch Med Wewn; 2001 Sep; 106(3):801-7. PubMed ID: 11928589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
